

# Michael Bhm

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3820666/michael-bohm-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418 papers	47,892 citations	93 h-index	215 g-index
452 ext. papers	62,482 ext. citations	8.7 avg, IF	7.09 L-index

#	Paper	IF	Citations
418	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , <b>2012</b> , 33, 1787-817	9.5	3691
417	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2013</b> , 34, 2159-219	9.5	3400
416	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1281-357	1.9	3363
415	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1995-2008	59.2	2021
414	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 803-69	12.3	1892
413	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , <b>2010</b> , 376, 875-85	40	1646
412	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1903-9	40	1577
411	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Journal of Clinical Investigation</i> , <b>2008</b> , 38, 197-203	12.3	1355
410	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 929-38	59.2	1260
409	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	59.2	1099
408	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2248-61	59.2	1098
407	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). <i>European Heart Journal</i> , <b>2005</b> , 26, 215-25	9.5	1076
406	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , <b>2021</b> , 42, 3599-3726	9.5	875
405	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 886-94	40	615
404	Update on myocarditis. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 779-92	15.1	587
403	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , <b>2014</b> , 383, 1933-43	40	469
402	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , <b>2014</b> , 383, 622-9	40	455

401	Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. <i>Circulation</i> , <b>2011</b> , 123, 1940-6	16.7	446
400	Predictors of outcome in patients with suspected myocarditis. <i>Circulation</i> , <b>2008</b> , 118, 639-48	16.7	442
399	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , <b>2015</b> , 131, 54-61	16.7	430
398	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2160-2170	40	406
397	Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 901-9	15.1	396
396	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2346-2355	40	358
395	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1451-1461	59.2	358
394	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. <i>Circulation</i> , <b>2012</b> , 126, 2976-82	16.7	343
393	Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 2150-8	15.1	311
392	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2335-2345	40	301
391	Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. <i>Circulation</i> , <b>2010</b> , 122, 900-9	16.7	271
390	Renal denervation in moderate to severe CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 1250-7	12.7	271
389	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1125-35	27.4	248
388	Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. <i>Circulation</i> , <b>2009</b> , 120, 2438-47	16.7	248
387	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 26-35	9.5	245
386	Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Hypertension</i> , <b>2012</b> , 60, 419-24	8.5	245
385	Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. <i>European Heart Journal</i> , <b>2011</b> , 32, 2034-41	9.5	245
384	Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. <i>Brain Research</i> , <b>2002</b> , 942, 23-30	3.7	245

383	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 1360-9	1.9	242
382	Elevated cytosolic Na <sup>+</sup> increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. <i>Circulation</i> , <b>2010</b> , 121, 1606-13	16.7	230
381	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , <b>2011</b> , 32, 2507-15	9.5	207
380	Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. <i>Cell Metabolism</i> , <b>2015</b> , 22, 472-84	24.6	206
379	Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. <i>Circulation</i> , <b>2013</b> , 128, 132-40	16.7	199
378	Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , <b>2008</b> , 117, 2377-87	16.7	197
377	Evidence for reduction of norepinephrine uptake sites in the failing human heart. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 25, 146-53	15.1	191
376	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1752-9	9.5	186
375	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 63-7	6.1	186
374	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , <b>2013</b> , 34, 2149-57	9.5	184
373	Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart Failure treatment with the I(f) inhibitor ivabradine Trial) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1938-45	15.1	183
372	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , <b>2017</b> , 136, 1374-1383	16.7	179
371	Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. <i>Hypertension</i> , <b>2012</b> , 60, 172-8	8.5	179
370	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , <b>2017</b> , 389, 2226-2237	40	171
369	Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. <i>Heart Rhythm</i> , <b>2011</b> , 8, 1436-43	6.7	170
368	Vascular pathophysiology in response to increased heart rate. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1973-83	15.1	168
367	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1444-1451	40	166
366	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 105-116	59.2	164

365	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. <i>European Heart Journal</i> , <b>2017</b> , 38, 2671-2679	9.5	160
364	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. <i>Clinical Research in Cardiology</i> , <b>2013</b> , 102, 11-22	6.1	157
363	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1353-1368	27.4	155
362	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 299-303	12.3	148
361	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 665-675	12.3	145
360	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 2683-93	27.4	145
359	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, Chinese Heart Failure Association, European Association of Preventive Cardiology, and the	12.3	143
358	Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONGOing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. <i>Circulation</i> , <b>2010</b> , 121, 1439-46	16.7	142
357	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , <b>2011</b> , 32, 2395-404	9.5	141
356	First report of the Global SYMPPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. <i>Hypertension</i> , <b>2015</b> , 65, 766-74	8.5	139
355	Sympatho-renal axis in chronic disease. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 1049-57	6.1	135
354	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1287	12.3	133
353	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2885-2896	15.1	132
352	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2481-93	15.1	130
351	Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. <i>Circulation</i> , <b>2021</b> , 143, 1157-1172	16.7	130
350	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1766-1775	15.1	126
349	Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONGOing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 74-83	15.1	126
348	Virus serology in patients with suspected myocarditis: utility or futility?. <i>European Heart Journal</i> , <b>2011</b> , 32, 897-903	9.5	124

347	Aldosterone promotes atrial fibrillation. <i>European Heart Journal</i> , <b>2012</b> , 33, 2098-108	9.5	119
346	Fluid status telemedicine alerts for heart failure: a randomized controlled trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 3154-3163	9.5	116
345	Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1956-65	15.1	115
344	Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1176-82	15.1	115
343	Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. <i>Circulation</i> , <b>2011</b> , 123, 209-15	16.7	114
342	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1495-1503	12.3	111
341	Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. <i>Heart Rhythm</i> , <b>2013</b> , 10, 1525-30	6.7	111
340	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , <b>2017</b> , 38, 1132-1143	9.5	109
339	Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 219-28	2.4	109
338	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 2224-31b	9.5	109
337	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , <b>2016</b> , 171, 82-91	4.9	104
336	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2031-45	15.1	104
335	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 2214-20	3.2	101
334	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 991-6	1.9	100
333	Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. <i>Hypertension</i> , <b>2013</b> , 62, 767-74	8.5	98
332	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 665-71	12.3	97
331	Atrial autonomic innervation: a target for interventional antiarrhythmic therapy?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 215-24	15.1	97
330	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , <b>2012</b> , 33, 2813-20	9.5	97



329	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , <b>2019</b> , 40, 3474-3482	9.5	95
328	Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2846-51	3.2	94
327	Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. <i>Hypertension</i> , <b>2013</b> , 61, 225-31	8.5	94
326	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. <i>European Heart Journal</i> , <b>2016</b> , 37, 2823-2829	9.5	93
325	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 716-726	59.2	92
324	Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 149-59	6.1	92
323	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1977-1985	15.1	90
322	Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. <i>European Heart Journal</i> , <b>2013</b> , 34, 2839-49	9.5	87
321	Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study. <i>European Heart Journal</i> , <b>2019</b> , 40, 34-46	9.5	85
320	Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. <i>Hypertension</i> , <b>2015</b> , 65, 193-9	8.5	84
319	Low-grade albuminuria and cardiovascular risk : what is the evidence?. <i>Clinical Research in Cardiology</i> , <b>2007</b> , 96, 247-57	6.1	84
318	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	84
317	Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1916-23	15.1	81
316	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
315	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , <b>2017</b> , 38, 93-100	9.5	79
314	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. <i>Nature Immunology</i> , <b>2020</b> , 21, 30-41	19.1	78
313	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 1261-6	1.9	77
312	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 11-9	6.1	76

311	The role of renal denervation in the treatment of heart failure. <i>Current Cardiology Reports</i> , <b>2012</b> , 14, 285-92	4.2	75
310	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , <b>2012</b> , 33, 2804-12	9.5	75
309	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1361-1378	12.3	73
308	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3	73
307	Renal denervation in moderate treatment-resistant hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1880-6	15.1	73
306	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , <b>2013</b> , 34, 2263-70	9.5	72
305	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 75-81	12.3	72
304	Management of atrial fibrillation in patients with heart failure. <i>European Heart Journal</i> , <b>2007</b> , 28, 2568-70	9.5	70
303	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 298-309	16.7	69
302	Strategies to improve drug adherence. <i>European Heart Journal</i> , <b>2011</b> , 32, 264-8	9.5	68
301	The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 343, 253-7	4.7	68
300	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , <b>2015</b> , 36, 434-9	9.5	66
299	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1315-1322	12.3	62
298	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 1097-105	6.1	61
297	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 2317-24	1.9	61
296	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 778-87	12.3	60
295	Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. <i>Hypertension</i> , <b>2015</b> , 65, 651-61	8.5	60
294	Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. <i>Stroke</i> , <b>2011</b> , 42, 1742-9	6.7	60



293	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , <b>2019</b> ,	16.7	58
292	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1893-900	1.9	57
291	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 873-9	6.1	55
290	Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?. <i>Circulation Research</i> , <b>2014</b> , 115, 400-9	15.7	55
289	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 3105-3114	9.5	54
288	Physicians guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 921-929	12.3	53
287	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1891-1901	12.3	52
286	Circulating microparticles as indicators of peripartum cardiomyopathy. <i>European Heart Journal</i> , <b>2012</b> , 33, 1469-79	9.5	52
285	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1040-1054	16.7	52
284	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1296-303	12.3	51
283	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1294-301	12.3	51
282	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 810-6	12.3	51
281	Renal sympathetic denervation: applications in hypertension and beyond. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 465-76	14.8	51
280	Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 18-25	1.9	51
279	Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. <i>European Heart Journal</i> , <b>2012</b> , 33, 1223-31	9.5	50
278	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 4-131	12.3	50
277	Catheter-based renal denervation reduces atrial nerve sprouting and complexity of atrial fibrillation in goats. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2015</b> , 8, 466-74	6.4	49
276	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1890-7	3	48

275	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2476-2486	4 <sup>0</sup>	47
274	Interstitial remodeling in beta1-adrenergic receptor transgenic mice. <i>Basic Research in Cardiology</i> , <b>2007</b> , 102, 183-93	11.8	46
273	Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 256-65	2.3	45
272	Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink). <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 796-804	12.3	45
271	Renal denervation and heart failure. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 608-13	12.3	44
270	Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. <i>American Heart Journal</i> , <b>2013</b> , 166, 306-314.e7	4.9	44
269	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 911-7	6.1	44
268	Incidence and prevalence of pregnancy-related heart disease. <i>Cardiovascular Research</i> , <b>2014</b> , 101, 554-60	9.9	44
267	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 743-751	9.5	44
266	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 518-26	12.3	43
265	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 364-71	6.1	42
264	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. <i>EuroIntervention</i> , <b>2013</b> , 9, 484-92	3.1	42
263	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2879-2888	15.1	41
262	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1079-1098	6.1	41
261	Drug adherence in patients taking oral anticoagulation therapy. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 173-82	6.1	41
260	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2147-2156	12.3	41
259	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 872-881	12.3	41
258	Role of autonomic nervous system in atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2019</b> , 287, 181-188	3.2	41

257	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , <b>2017</b> , 188, 99-108	4.9	40
256	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 885-91	12.3	40
255	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , <b>2020</b> , 41, 3402-3418	9.5	40
254	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , <b>2013</b> , 18, 107-22	5	39
253	Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. <i>Journal of Cardiology</i> , <b>2013</b> , 62, 183-7	3	39
252	Effects of electrical stimulation of carotid baroreflex and renal denervation on atrial electrophysiology. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2013</b> , 24, 1028-33	2.7	38
251	Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 497-503	3	37
250	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	37
249	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1095-1105	5	36
248	Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. <i>European Heart Journal</i> , <b>2009</b> , 30, 1364-71	9.5	36
247	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1017-1028	15.1	35
246	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , <b>2020</b> , 41, 3787-3797	9.5	35
245	Device-based therapies for arterial hypertension. <i>Nature Reviews Cardiology</i> , <b>2020</b> , 17, 614-628	14.8	35
244	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1446-1459	6.1	34
243	Beneficial association of $\beta$ -blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. <i>Critical Care Medicine</i> , <b>2011</b> , 39, 940-4	1.4	34
242	Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1012-1021	12.3	33
241	Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?. <i>Drugs</i> , <b>2010</b> , 70, 1215-30	12.1	33
240	Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 38J-44J	3	33

239	Renal denervation: effects on atrial electrophysiology and arrhythmias. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 765-74	6.1	32
238	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 2519-25	1.9	32
237	Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 1633-40	1.9	32
236	Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. <i>Atherosclerosis</i> , <b>2010</b> , 212, 55-62	3.1	32
235	Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure- and Heart Rate-Independent Manner. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 972-80	5	31
234	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 426-34	12.3	31
233	Response and non-response to renal denervation: who is the ideal candidate?. <i>EuroIntervention</i> , <b>2013</b> , 9 Suppl R, R54-7	3.1	31
232	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 471-484	5	30
231	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 126-135	12.3	30
230	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1182-9	12.3	30
229	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , <b>2018</b> , 138, 1602-1604	16.7	28
228	Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. <i>Cardiovascular Research</i> , <b>2016</b> , 110, 371-80	9.9	27
227	Exercise promotes collateral artery growth mediated by monocytic nitric oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1862-71	9.4	26
226	Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. <i>Trends in Cardiovascular Medicine</i> , <b>2009</b> , 19, 152-7	6.9	26
225	Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. <i>Clinical Research in Cardiology</i> , <b>2009</b> , 98, 513-5	6.1	26
224	BEAUTIFUL results--the slower, the better?. <i>Lancet, The</i> , <b>2008</b> , 372, 779-80	40	26
223	Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. <i>International Journal of Cardiology</i> , <b>2013</b> , 169, 418-24	3.2	25
222	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 165-7	3.2	25

221	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1230-1241	12.3	24
220	Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. <i>International Journal of Cardiology</i> , <b>2015</b> , 190, 376-82	3.2	24
219	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 373-381	12.3	24
218	Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176311	3.7	24
217	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. <i>EuroIntervention</i> , <b>2020</b> , 16, 89-96	3.1	24
216	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2032-2043	9.5	23
215	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1644-1656	15.1	23
214	Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1021-1030	12.3	23
213	Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. <i>Hypertension</i> , <b>2014</b> , 63, 839-45	8.5	23
212	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1500-1506	6.1	23
211	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 254-264	7.9	23
210	Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 665-73	6.1	22
209	Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. <i>EuroIntervention</i> , <b>2013</b> , 9, 700-8	3.1	22
208	Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 676-684	12.3	21
207	Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 601-12	6.1	21
206	Effect of Combining Ivabradine and BBlockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , <b>2015</b> , 131, 218-24	1.6	21
205	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2909-2919	15.1	21
204	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1733-1741	1.9	21



203	Heart rate differentiates urgency and emergency in hypertensive crisis. <i>Clinical Research in Cardiology</i> , <b>2013</b> , 102, 593-8	6.1	20
202	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1623-1632	16.7	20
201	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , <b>2021</b> , 42, 1742-1756	9.5	20
200	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 991-1002	6.1	20
199	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , <b>2017</b> , 241, 373-378	3.2	19
198	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 552-562	12.3	19
197	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , <b>2017</b> , 70, 938-948	8.5	19
196	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011183	6	19
195	Analyses of drugs stored at home by elderly patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 320-7	6.1	19
194	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1044-52	12.3	19
193	Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. <i>Journal of Vascular Research</i> , <b>2012</b> , 49, 432-40	1.9	19
192	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i> , <b>2020</b> , 76, 1410-1417	8.5	18
191	Marathon running increases circulating endothelial- and thrombocyte-derived microparticles. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 317-324	3.9	18
190	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEsus trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 1673-1683	9.5	17
189	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 290-297	6.1	17
188	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 325-33	12.3	17
187	Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 2512-8	1.9	17
186	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 1064-71	6.1	17



185	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 2480-2486	1.9	17
184	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	17
183	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 755-62	6.1	17
182	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2893-2904	15.1	17
181	Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1948-1953	3	16
180	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 1854-62	1.9	16
179	Association of vitamin D status and blood pressure response after renal denervation. <i>Clinical Research in Cardiology</i> , <b>2014</b> , 103, 41-7	6.1	16
178	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 528-538	12.3	16
177	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , <b>2020</b> , 41, 231-238	9.5	16
176	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry. <i>Journal of Hypertension</i> , <b>2017</b> , 35, 148-153	1.9	15
175	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 289-302	6.1	15
174	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 672-83	12.3	15
173	PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1350-1359	12.3	15
172	Hypertension: history and development of established and novel treatments. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 16-29	6.1	15
171	Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 783-790	1.9	14
170	Procollagen propeptides: serum markers for atrial fibrosis?. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 655-61	6.1	14
169	Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 1023-1031	1.9	14
168	Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. <i>Clinical Autonomic Research</i> , <b>2018</b> , 28, 375-384	4.3	13

167	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 642-652	6.1	13
166	Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. <i>Clinical Cardiology</i> , <b>2015</b> , 38, 200-7	7.3	13
165	Recent advances in the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 729-44	2.5	13
164	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 1962-1972	16.7	13
163	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 6	8.7	13
162	Thrombus aspiration in non-ST-elevation myocardial infarction - 12-month clinical outcome of the randomised TATORT-NSTEMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2017</b> , 6, 10-17	4.3	12
161	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , <b>2019</b> , HYPERTENSIONAHA11913081	8.5	12
160	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. <i>Cardiology</i> , <b>2017</b> , 136, 138-144	1.6	12
159	Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 813-20	6	12
158	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	12
157	Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 810-818	6.1	12
156	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 2848-2859	9.5	11
155	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. <i>Journal of Hypertension</i> , <b>2014</b> , 32, 1334-41	1.9	11
154	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 845-856	6.1	11
153	MicroRNA-mediated vascular intercellular communication is altered in chronic kidney disease. <i>Cardiovascular Research</i> , <b>2020</b> ,	9.9	11
152	Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. <i>Patient Preference and Adherence</i> , <b>2019</b> , 13, 9-19	2.4	11
151	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , <b>2022</b> , 399, 1401-1410	4.0	11
150	Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 482-491	12.3	10

149	The association between different features of sleep-disordered breathing and blood pressure: A cross-sectional study. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 575-581	2.3	10
148	Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 167	8.5	10
147	From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. <i>Cardiology</i> , <b>2010</b> , 117, 163-73	1.6	10
146	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , <b>2018</b> , 14, 121-128	3.1	10
145	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1829-1840	1.9	10
144	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPPLICITY Registry. <i>Journal of Clinical Hypertension</i> , <b>2017</b> , 19, 833-839	2.3	9
143	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1469-1472	12.3	9
142	A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 545-52	5	9
141	Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 272-80	3.9	9
140	Treating resistant hypertension: role of renal denervation. <i>Integrated Blood Pressure Control</i> , <b>2013</b> , 6, 119-28	3.5	9
139	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. <i>Korean Circulation Journal</i> , <b>2017</b> , 47, 9-15	2.2	8
138	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. <i>Cardiovascular Revascularization Medicine</i> , <b>2018</b> , 19, 845-851	1.6	8
137	Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis. <i>European Heart Journal</i> , <b>2018</b> , 39, 2330-2331	9.5	8
136	Research in Atrial Fibrillation: A Scientometric Analysis Using the Novel Web Application SciPE. <i>JACC: Clinical Electrophysiology</i> , <b>2020</b> , 6, 1008-1018	4.6	8
135	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 861-871	3.7	8
134	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1337-1348	15.1	8
133	Interleukin-1 $\beta$ is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. <i>Circulation</i> , <b>2021</b> , 144, 893-908	16.7	8
132	Cathepsin A Mediates Ventricular Remote Remodeling and Atrial Cardiomyopathy in Rats With Ventricular Ischemia/Reperfusion. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 332-344	8.7	7

131	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1199-1207	3.7	7
130	Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. <i>EuroIntervention</i> , <b>2013</b> , 9 Suppl R, R122-6	3.1	7
129	Time-updated resting heart rate predicts mortality in patients with COPD. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 776-786	6.1	7
128	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. <i>European Heart Journal</i> , <b>2020</b> , 41, 2556-2569	9.5	7
127	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. <i>Journal of Human Hypertension</i> , <b>2021</b> , 35, 903-911	2.6	7
126	Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007421	7.6	7
125	Effects of face masks on performance and cardiorespiratory response in well-trained athletes. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	7
124	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 725-731	6.1	7
123	Repeated exposure to transient obstructive sleep apnea-related conditions causes an atrial fibrillation substrate in a chronic rat model. <i>Heart Rhythm</i> , <b>2021</b> , 18, 455-464	6.7	7
122	Publication performance of women compared to men in German cardiology. <i>International Journal of Cardiology</i> , <b>2015</b> , 181, 267-9	3.2	6
121	Witnessed drug intake before planned denervation--always harmless?. <i>International Journal of Cardiology</i> , <b>2015</b> , 179, 125-6	3.2	6
120	Development, establishment and validation of in vitro and ex vivo assays of vascular calcification. <i>Biochemical and Biophysical Research Communications</i> , <b>2020</b> , 530, 462-470	3.4	6
119	Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2018</b> , 122, 34-46	5.8	6
118	Heart rate and heart failure: the role of ivabradine therapy. <i>Current Opinion in Cardiology</i> , <b>2013</b> , 28, 326-331	3.1	6
117	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 2416-2426	1.9	6
116	Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.3	6
115	Myopathic Cardiac Genotypes Increase Risk for Myocarditis. <i>JACC Basic To Translational Science</i> , <b>2021</b> , 6, 584-592	8.7	6
114	Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 581-588	6.1	6

113	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 2453-2459	1.9	6
112	Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014180	6	5
111	The new SFB/TRR219 Research Centre. <i>European Heart Journal</i> , <b>2018</b> , 39, 975-977	9.5	5
110	Renal Denervation: Is It Ready for Prime Time?. <i>Current Cardiology Reports</i> , <b>2019</b> , 21, 80	4.2	5
109	Renal denervation: a novel non-pharmacological approach in heart failure. <i>Journal of Cardiovascular Translational Research</i> , <b>2014</b> , 7, 330-7	3.3	5
108	Novel and nonpharmacologic approaches to cardio-protection in hypertension. <i>Current Hypertension Reports</i> , <b>2014</b> , 16, 430	4.7	5
107	Effects of renal denervation on atrial arrhythmogenesis. <i>Future Cardiology</i> , <b>2014</b> , 10, 813-22	1.3	5
106	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTITUDE, FAME II and more. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 861-74	6.1	5
105	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	5
104	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 420-425	1.9	5
103	A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 1	6.1	5
102	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3310	3.7	5
101	The current status of renal denervation for the treatment of arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 65, 76-83	8.5	5
100	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , <b>2021</b> , 16, e1496-e1502	3.1	5
99	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3122	1.8	5
98	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 1906-1912	1.9	5
97	Determinants of HIV-1 Late Presentation in Patients Followed in Europe. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	5
96	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1028-1038	15.1	5

95	Renal nerve ablation. <i>Heart</i> , <b>2015</b> , 101, 320-8	5.1	4
94	Accuracy of pulse rate derived from 24-h ambulatory blood pressure monitoring compared with heart rate from 24-h Holter-ECG. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 2387-2392	1.9	4
93	Overview of the i-SEARCH Global Study : Cardiovascular Risk Factors and Microalbuminuria in Hypertensive Individuals. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2008</b> , 15, 217-24	2.9	4
92	Time is prognosis in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4444	3.7	4
91	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e24514	7.6	4
90	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1960-1970	12.3	4
89	Drug Layering in Heart Failure: Phenotype-Guided Initiation. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 775-783	7.9	4
88	Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2502-2512	3.7	4
87	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2814-2818	6.7	4
86	Hypertension trials update. <i>Journal of Human Hypertension</i> , <b>2021</b> , 35, 398-409	2.6	4
85	CardioPulse. Catheter-based renal denervation for hypertension treatment: update 2015. <i>European Heart Journal</i> , <b>2016</b> , 37, 930-3	9.5	4
84	Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study.. <i>Lancet Rheumatology</i> , <b>2022</b> ,	14.2	4
83	Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial : Thrombus aspiration in acute myocardial infarction. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1223-1231	6.1	3
82	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	3
81	Loss of Mitochondrial Ca Uniporter Limits Inotropic Reserve and Provides Trigger and Substrate for Arrhythmias in Barth Syndrome Cardiomyopathy. <i>Circulation</i> , <b>2021</b> , 144, 1694-1713	16.7	3
80	Comparison of Long-Term Outcomes for Responders Versus Non-Responders Following Renal Denervation in Resistant Hypertension. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e022429	6	3
79	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1150-1158	6.1	3
78	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , <b>2021</b> , 149, 27-35	3	3



77	The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3566-3576	3.7	3
76	Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 574-576	6.1	3
75	Valvular heart disease in patients with chronic kidney disease. <i>Herz</i> , <b>2021</b> , 46, 228-233	2.6	3
74	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia.. <i>Clinical Research in Cardiology</i> , <b>2022</b> , 1	6.1	3
73	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , <b>2022</b> , 145, 847-863	16.7	3
72	Hypertension: Arteriovenous anastomosis--next panacea for hypertension?. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 197-8	14.8	2
71	Wissenschaftslandschaft Deutschland. <i>Kardiologe</i> , <b>2020</b> , 14, 113-123	0.6	2
70	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 631; author reply 631-2	12.3	2
69	Sex Differences in Cardiovascular Research: A Scientometric Analysis. <i>Journal of the American Heart Association</i> , <b>2021</b> , e021522	6	2
68	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 1807-1816	2.3	2
67	Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2021</b> , 44, 667-676	1.6	2
66	The significance of left ventricular ejection time in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 541-551	12.3	2
65	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 766-774	1.9	2
64	High blood pressure in coronary artery disease: when to start treating and what to target?. <i>European Heart Journal</i> , <b>2018</b> , 39, 3864-3866	9.5	2
63	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 1493-1503	2.6	2
62	Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study.. <i>Integrated Blood Pressure Control</i> , <b>2022</b> , 15, 11-21	3.5	2
61	Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial.. <i>Clinical Research in Cardiology</i> , <b>2022</b> , 1	6.1	2
60	Management strategies in heart failure with preserved ejection fraction.. <i>Herz</i> , <b>2022</b> , 1	2.6	2

59	Vena Cava Compression Syndrome in Obesity is Reversed by Bariatric Surgery. <i>American Journal of Medicine</i> , <b>2018</b> , 131, e291-e292	2.4	1
58	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , <b>2017</b> , 249, 365	3.2	1
57	Drug therapy for the patient with resistant hypertension. <i>Future Cardiology</i> , <b>2015</b> , 11, 191-202	1.3	1
56	Application in Hypertension of Renal Sympathetic Denervation - A Review. <i>Interventional Cardiology Review</i> , <b>2013</b> , 8, 124-126	4.2	1
55	"Dear Doctor" Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. <i>Deutsches Arzteblatt International</i> , <b>2020</b> , 117, 687-688	2.5	1
54	Treating to protect: current cardiovascular treatment approaches and remaining needs. <i>Medscape Journal of Medicine</i> , <b>2008</b> , 10 Suppl, S3		1
53	Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	1
52	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis (Preprint)		1
51	Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 12605-12617	5.4	1
50	Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure. <i>European Heart Journal</i> , <b>2020</b> , 41, 4600	9.5	1
49	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 665-674	3.3	1
48	Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non-dialysis CKD: An observational study. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00801	3.1	1
47	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 938-958	6.1	1
46	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, 1064-71	1.9	1
45	Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, M68-M71	1.5	1
44	The Current Status of Devices for the Treatment of Resistant Hypertension. <i>American Journal of Hypertension</i> , <b>2020</b> , 33, 10-18	2.3	1
43	Letter on PPharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trialP reply. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 565-566	12.3	1
42	Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure: Results From the OptiLink HF Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e008693	6.4	1

41	Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1697-1704	1.9	1
40	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. <i>Atherosclerosis</i> , <b>2021</b> , 330, 8-13	3.1	1
39	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , <b>2021</b> , 23, 100818	1.8	1
38	Arterial hypertension - Clinical trials update 2021. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> ,	4.5	1
37	Pathophysiology: The Target for Renal Denervation <b>2015</b> , 1-7		1
36	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. <i>Hypertension</i> , <b>2022</b> , 101161HYPERTENSIONAHA12118641	8.5	1
35	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	1
34	Reply: Anticoagulant-Related Nephropathy. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2682-2683	5.1	0
33	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 12	8.7	0
32	Sodium-Glukose-Transporter 2 (SGLT2)-Hemmer bei Herzinsuffizienz. <i>Kardiologie</i> , <b>2022</b> , 16, 46-52	0.6	0
31	Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD.. <i>Circulation Research</i> , <b>2022</b> , CIRCRESAHA121320104	15.7	0
30	Experimental Evidence Of The Role Of Renal Sympathetic Denervation For Treating Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2014</b> , 7, 1128	0.8	0
29	Optimization of Heart Failure Treatment by Heart Rate Reduction. <i>International Journal of Heart Failure</i> , <b>2020</b> , 2, 1	1.3	0
28	Arterielle Hypertonie [Was war 2020 wichtig?]. <i>Kardiologie</i> , <b>2021</b> , 15, 127-132	0.6	0
27	COVID-19 and the heart: insights from the National Societies of Cardiology Journals. <i>European Heart Journal</i> , <b>2021</b> , 42, 4003-4005	9.5	0
26	Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome. <i>IJC Heart and Vasculature</i> , <b>2021</b> , 34, 100757	2.4	0
25	Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL / Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von Renale-Denervations-Zentren (RDZ) Update. <i>Kardiologie</i> , <b>2021</b> , 15, 463-470	0.6	0
24	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1602-1610	1.9	0

23	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , <b>2022</b> , CIRCHEARTFAILURE121008970	7.6	o
22	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> ,	3.7	o
21	Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects. <i>American Journal of Hypertension</i> , <b>2019</b> , 32, 935-937	2.3	
20	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. <i>JACC: Case Reports</i> , <b>2020</b> , 2, 384-388	1.2	
19	Target blood pressure in high risk cardiovascular patients. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, E877-E878.	8.6	
18	Early renin-angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes. <i>Evidence-Based Medicine</i> , <b>2017</b> , 22, 185-186		
17	Overestimation of cardiovascular outcome incidence - AuthorsPreply. <i>Lancet, The</i> , <b>2017</b> , 390, 2547	4.0	
16	Response to letter regarding article, "renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?". <i>Circulation Research</i> , <b>2014</b> , 115, e19-20	15.7	
15	Does angiotensin-converting-enzyme inhibitor therapy improve cognitive function in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2005</b> , 2, 448-9		
14	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , <b>2021</b> , 1	0.8	
13	Renal Denervation for Chronic Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2016</b> , 281-292	0.1	
12	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, 1068-1075	1.9	
11	J-curve revisited. <i>European Heart Journal</i> , <b>2020</b> , 41, 4283	9.5	
10	Kardiovaskuläre Forschung in Deutschland 2020 – eine szientometrische Analyse. <i>Kardiologe</i> , <b>2021</b> , 15, 160-167	0.6	
9	Therapie bei Diabetes und Niereninsuffizienz. <i>Kardiologe</i> , <b>2021</b> , 15, 133-139	0.6	
8	Blood pressure and renal denervation with ultrasound: another step forward. <i>Lancet, The</i> , <b>2021</b> , 397, 2441-2443	4.0	
7	Neue Therapiekonzepte der HfrEF. <i>Kardiologie Up2date</i> , <b>2021</b> , 17, 267-279	0	
6	Innovationen in der medikamentösen Therapie der Herzinsuffizienz. <i>CardioVasc</i> , <b>2021</b> , 21, 39-46	0	

- |   |  |     |
|---|--|-----|
| 5 | Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , <b>2021</b> , 98, E832-E838 | 2.7 |
| 4 | Differences in management of telemedicine alerts on weekdays and public holidays: Results from the OptiLink heart failure trial. <i>Journal of Telemedicine and Telecare</i> , <b>2021</b> , 1357633X211039398                         | 6.8 |
| 3 | Catheter-based renal denervation: treating hypertension or beyond?. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 1166-8   | 2.9 |
| 2 | Ischemic Stroke-A Scientometric Analysis.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 893121  | 4.1 |
| 1 | Herz und Niere. <i>Springer Reference Medizin</i> , <b>2022</b> , 1-15   | 0   |